Dalmia Healthcare will soon be announcing the launch of the polyherbal combination of 15 herbs called Astha-15 for the treatment of Covid-19 and standard care approved as per Ayush/ICMR guidelines. This Ayurvedic (Indian System of Medicine) polyherbal capsule has been developed with the rationale to provide a safe and effective Ayurvedic formulation for the patients suffering from Covid and shown remarkable results.
“This is a proud moment for India, our own indigenous Ayurveda and Dalmia Healthcare –has developed Astha-15 for the effective treatment of respiratory disorders in Covid patients,” says Sanjay Dalmia, chairman, Dalmia Group of Companies. Dalmia’s research arm Dalmia Centre for Research and Development (DCRD) has developed Astha-15 after extensive research and developed this polyherbal combination.
“We are happy to announce that the outcome of the clinical trial showed that Astha-15 has significantly reduced the cough and wheezing, improved the respiratory rate and aid in the speedy recovery of Covid-19 patients with the improvement of quality of life during the treatment cycle,” asserts Dalmia.
The company said aptly named Astha or faith, Astha-15 brings back the faith of Ayurveda’s healthcare fraternity. The pathbreaking medicine acts as a bronchodilator, decongestant, anti-inflammatory, and lung detoxifier. It helps in eliminating the infection and regulating the allergic reactions. This has a specific action on the mucosa of the respiratory tract and the lungs’ muscular walls that act as the airways. It has an anti-inflammatory effect, which reduces inflammation and congestion inside the lungs. Its continuous use reduces the damage on the lungs and the muscular walls and brings out a significant reversal in their dysfunction. All these disorders which have been found in Covid-19 patients have been confirmed to be treated by Astha-15.
Dalmia Healthcare had earlier sought approval for Astha-15 by conducting a clinical trial to evaluate the efficacy and safety of polyherbal combination for the treatment of Covid-19 along with standard care approved as per Ayush/ICMR guidelines. After two successful phases, the Phase III trial was conducted on 120 subjects at multi-centric sites viz. JNUIMSRC, Jaipur, Government Medical College & Govt. General hospital, Srikakulam (Old RIMSGGH) and RGMC & CSMH, Thane by following Ayush’s regulatory guidelines and the Informed Consent Declaration, Insurance Terms, and Hospital Ethics Committee approvals which are registered at DCGI to perform the clinical trial, it said. This phase III clinical trial has been registered on CTRI with reg. no. CTRI/2020/06/025590.
According to Dalmia, Astha-15 will be made available in the first phase through prescriptions written for mild and moderate Covid patients undergoing treatment in Covid hospitals. Dalmia Healthcare would be applying for permission or approval of Astha-15 usage in allopathic hospitals, as per the procedure in each hospital.
Dalmia’s Astha-15 will be the first Ayurvedic drug and an indigenous formulation from India in the global market addressing the respiratory disorders in Covid. Its arrival will bring in immediate faster recovery relief to lakhs of Covid patients.
Dalmia Healthcare has made entry into the healthcare business in the year 2000. It offers plant-based formulations (Ayurvedic or herbal) prepared through scientific validation followed by clinical trials undertaken by its research center, Dalmia Centre for Research and Development (DCRD).
The essence of pre-marketing efforts focuses on clinical trials compared and measured with those for various Allopathic drugs indicated for similar conditions. Extensive toxicological studies are conducted while formulating DHL products to ensure that our products are safe and devoid of adverse side-effects. All products of Dalmia Healthcare are manufactured and evaluated following the standards of modern medical parameters.
